TY - JOUR
T1 - Evaluating the current neuro-oncology capacity in Sub-Saharan Africa
T2 - A questionnaire-based survey
AU - Zerd, Francis
AU - Odukoya, Lateef A.
AU - Cheserem, Beverly
AU - Darko, Kwadwo
AU - Ghomsi, Nathalie C.
AU - Kabare, Gloria S.
AU - Kamson, David O.
AU - Eckel-Passow, Jeanette E.
AU - Jenkins, Robert B.
AU - Decker, Paul
AU - Llewellyn, Henry
AU - Kitange, Gaspar J.
AU - Akinjo, Andrea O.
AU - Badmos, Kabir B.
AU - Yevudza, W. Elorm
AU - Bankole, Olufemi
AU - Idowu, Olufemi E.
AU - Ayanlaja, Abiola Abdulrahman
AU - Karekezi, Claire
AU - Edrick, Elias
AU - Ekhator, Chukwuyem
AU - Katasi, Victoria M.
AU - Lachance, Daniel H.
AU - Huse, Jason
AU - Magambo, Margreth
AU - Banti, Eyerusalem
AU - Magoha, Michael
AU - Ngaiza, Advera
AU - Nyalundja, Arsene D.
AU - Higgins, Dominique
AU - Okemwa, Minda
AU - Osei-Tutu, Lawrence
AU - Petershie, Bernard
AU - Minja, Frank J.
AU - Anunobi, Charles C.
AU - Etame, Arnold B.
AU - Tiamiyu, Liadi
AU - Gankpe, Gbetoho Fortuné
AU - Kwikima, Ugumba Mussa
AU - Heronima, Kashaigili
AU - Schroeder, Kristin
AU - Muanza, Thierry
AU - Brown, Desmond A.
AU - Davidson, Alan
AU - Fonkem, Ekokobe
AU - Totimeh, Teddy
AU - Balogun, James
N1 - Publisher Copyright:
© The Author(s) 2025. All rights reserved. For commercial re-use, please contact [email protected] for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact [email protected].
PY - 2026/6
Y1 - 2026/6
N2 - Background: Central nervous system (CNS) tumors are a significant cause of morbidity and mortality in Sub-Saharan Africa (SSA). This project aimed to assess and map out the current neuro-oncology capacity in SSA, brain tumor registries, and biobanks. Methods: This cross-sectional study utilized an online survey to gather data from healthcare professionals involved in CNS tumor care across SSA through the Society for Neuro-Oncology SSA (SNOSSA). The survey captured information on the availability of neuro-oncology practitioners, neuropathology, molecular diagnostics, cancer registries, and biobanking. Results: A total of 145 respondents representing 70 healthcare institutions across 22 countries participated. Of the 70 institutions, specialties included neurosurgery (89%, 62/70), anatomic pathology (74%, 52/70), and medical oncology (71%, 50/70). For radiologic evaluation, 64% (45/70) of responding institutions reported having both CT and MRI. Access to molecular testing through immunohistochemistry or next-generation sequencing was available in 46% (32/70) of responding institutions. Multidisciplinary tumor boards were available for CNS cases in 86% (60/70) of responding institutions. Brain tumor-specific registries were available in 29% (20/70) of responding institutions, and 10% (7/70) maintained brain tumor biorepositories. Conclusion: This study demonstrates that SSA has substantial potential in neuro-oncology care practice capacity and facilities. The most significant gaps were in neuropathology and molecular testing, which makes widespread implementation of the WHO 2021 diagnosis challenging. Understanding the prevalence of CNS tumor subtypes in SSA is difficult due to the low number of brain tumor registries and biobanks.
AB - Background: Central nervous system (CNS) tumors are a significant cause of morbidity and mortality in Sub-Saharan Africa (SSA). This project aimed to assess and map out the current neuro-oncology capacity in SSA, brain tumor registries, and biobanks. Methods: This cross-sectional study utilized an online survey to gather data from healthcare professionals involved in CNS tumor care across SSA through the Society for Neuro-Oncology SSA (SNOSSA). The survey captured information on the availability of neuro-oncology practitioners, neuropathology, molecular diagnostics, cancer registries, and biobanking. Results: A total of 145 respondents representing 70 healthcare institutions across 22 countries participated. Of the 70 institutions, specialties included neurosurgery (89%, 62/70), anatomic pathology (74%, 52/70), and medical oncology (71%, 50/70). For radiologic evaluation, 64% (45/70) of responding institutions reported having both CT and MRI. Access to molecular testing through immunohistochemistry or next-generation sequencing was available in 46% (32/70) of responding institutions. Multidisciplinary tumor boards were available for CNS cases in 86% (60/70) of responding institutions. Brain tumor-specific registries were available in 29% (20/70) of responding institutions, and 10% (7/70) maintained brain tumor biorepositories. Conclusion: This study demonstrates that SSA has substantial potential in neuro-oncology care practice capacity and facilities. The most significant gaps were in neuropathology and molecular testing, which makes widespread implementation of the WHO 2021 diagnosis challenging. Understanding the prevalence of CNS tumor subtypes in SSA is difficult due to the low number of brain tumor registries and biobanks.
KW - Sub-Saharan Africa
KW - brain tumors
KW - central nervous system
KW - neuro-oncology
UR - https://www.scopus.com/pages/publications/105031190088
U2 - 10.1093/nop/npaf107
DO - 10.1093/nop/npaf107
M3 - Article
AN - SCOPUS:105031190088
SN - 2054-2577
VL - 13
SP - 537
EP - 548
JO - Neuro-Oncology Practice
JF - Neuro-Oncology Practice
IS - 3
ER -